Women with breast cancer who took statins regularly had significantly better breast cancer-specific survival than those who did not take any statins, a Swedish study has shown. [SABCS 2017, poster P2-13-03]
A recent study presented at the 2017 San Antonio Breast Cancer Symposium (SABCS) showed that acupuncture is effective in reducing aromatase inhibitor–induced joint symptoms among breast cancer patients.
Adding trastuzumab to standard adjuvant chemotherapy does not improve survival or reduce recurrence in patients with early-stage breast cancer expressing low levels of HER2, according to results of a National Surgical Adjuvant Breast and Bowel Project study reported at the 2017 San Antonio Breast Cancer Symposium (SABCS).
The phase IB/II PANACEA study recently showed that the addition of pembrolizumab to trastuzumab in patients with trastuzumab-resistant advanced HER2-positive breast cancer resulted in disease control with a tolerable safety profile.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Doctor - Malaysia digital copy today!
Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.
The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.